ACNT vs XFOR Comparison

Ascent Industries Co is engaged in the chemical and metal industry. The group operates into two reportable segments namely the Specialty Chemicals and Tubular Products. The Tubular Products segment serves markets through pipe and tube and customers in the appliance, architectural, automotive, and commercial transportation, brewery, chemical, petrochemical, and other industries. The Specialty Chemicals segment produces specialty products for pulp and paper, coatings, adhesives, sealants, and elastomers (CASE), textile, automotive, household, and other industries. It manufactures welded pipe and tube, majorly from stainless steel, duplex, and nickel alloys. The company also produces specialty chemicals and dyes used in various end markets.

X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.